Article citationsMore>>

Harrison, C., Kiladjian, J.J., Al-Ali, H.K., et al. (2012) JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. The New England Journal of Medicine, 366, 787-798.
https://doi.org/10.1056/NEJMoa1110556

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top